Sections
Shortcuts
Business

Biogen Idec chief warns drug development could be hurt by cuts in funding and reimbursements

Biogen Idec’s George Scangos said his company and others are stepping up but “can’t pick up all the slack.”
Biogen Idec’s George Scangos said his company and others are stepping up but “can’t pick up all the slack.”Jessica Rinaldi/globe staff

This is a summary. To read the whole story subscribe to BostonGlobe.com

The top executive of Biogen Idec Inc. said Thursday that the state’s drug makers are producing breakthrough treatments for conditions ranging from multiple sclerosis to hepatitis C to hemophilia.But he warned future innovation is threatened by federal funding cuts for basic research and payments that don’t allow companies to recover their investments.

Full story for BostonGlobe.com subscribers.

Get the full story with unlimited access to BostonGlobe.com.

Just 99 cents for four weeks.

Sections
Shortcuts

Share